Keywords: astrazeneca, atacand, reduces, atrial, fibrillation, hypertension, anglo-swedish
AstraZeneca's Atacand reduces atrial fibrillation in hypertension
Article | 10 July 2006
Anglo-Swedish drug major AstraZeneca says that data published in the American Heart Journal show that Atacand (candesartan cilexetil), its anti-hypertension ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
